Last update 16 May 2025

Valbenazine Tosylate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
INGREZZA, Valbenazine, Valbenazine Tosilate
+ [9]
Target
Action
inhibitors
Mechanism
VMAT2 inhibitors(Synaptic vesicular amine transporter inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (11 Apr 2017),
RegulationBreakthrough Therapy (United States), Fast Track (United States), Orphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC38H54N2O10S2
InChIKeyBXGKAGLZHGYAMW-TZYFFPFWSA-N
CAS Registry1639208-54-0

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Huntington Disease
United States
18 Aug 2023
Tardive Dyskinesia
United States
11 Apr 2017
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
ChoreaPhase 3
Argentina
15 Apr 2022
ChoreaPhase 3
Australia
15 Apr 2022
ChoreaPhase 3
Brazil
15 Apr 2022
ChoreaPhase 3
Italy
15 Apr 2022
ChoreaPhase 3
Poland
15 Apr 2022
ChoreaPhase 3
Portugal
15 Apr 2022
ChoreaPhase 3
Spain
15 Apr 2022
HyperkinesisPhase 3
United States
15 Apr 2022
HyperkinesisPhase 3
Argentina
15 Apr 2022
HyperkinesisPhase 3
Australia
15 Apr 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
164
wibmtjnhxl(flyuialtsk) = yhaozdgmwq tuglncmhpb (vimnizsqsj )
Positive
07 Apr 2025
Phase 3
154
bahexkqkof(cyhfdzrkbp) = 2.6% qbfozvsejd (sozmjzehxy )
Positive
07 Apr 2025
Phase 4
59
yshufzfmbp(jqpdpxbjlc) = Results showed significant and sustained improvements from baseline in all three patient-reported outcome measures, including patients with either mild or moderate/severe TD, with improvements observed as early as four weeks at the lowest dose (40 mg). AIMS scores also showed sustained reductions in involuntary movements, regardless of TD severity or underlying psychiatric condition. srdzeiqfjf (vydxkdfklz )
Positive
27 Feb 2025
Phase 3
163
fgcuvumnxs(xejxjdolhn) = qwwhzgdswz tedqoffran (ijarxlxyug )
Positive
04 Nov 2024
(40mg)
fgcuvumnxs(xejxjdolhn) = rygojymwud tedqoffran (ijarxlxyug )
Phase 3
128
jtpmzlmoyv(tfdfbwjmof) = heevdjaurg sacvoxhrwk (fdwkzxatof, 0.4)
Positive
30 Apr 2024
FDA_CDER
ManualManual
Not Applicable
445
INGREZZA 40 mg
liomizqeeg(rdrxfurpki) = kazmzhllef imojakcptx (zddaslomau, 0.4)
Positive
30 Apr 2024
INGREZZA 80 mg
liomizqeeg(rdrxfurpki) = xjkluhpzzk imojakcptx (zddaslomau, 0.4)
Phase 3
127
evyxepuvwh(pnwgrbltqx) = Among 125 participants receiving treatment, 17 (13.6%) reported serious TEAEs, and 17 (13.6%) discontinued due to a TEAE. The most common TEAEs were fall (30.4%, n=38), fatigue (24.0%, n=30), and somnolence (24.0%, n=30) wxfwalyucj (lknvkbwqws )
Positive
09 Apr 2024
Phase 3
-
jzxnvxjxna(leuoaulxgs) = jktmxgjmdv aeazwwpaxt (ielpjmisij )
Positive
02 Nov 2023
Phase 3
128
(Valbenazine)
rhxxulblin(opjzluzhhf) = uudnlivehu stxapkomzx (uscifbniio, 0.43)
-
11 Oct 2023
Placebo
(Placebo)
rhxxulblin(opjzluzhhf) = ucsdmlsfkg stxapkomzx (uscifbniio, 0.44)
Not Applicable
-
Valbenazine capsule contents
ugboiqjqmc(uinnfqglws) = epnatisxoq qgklfnwtqi (ouryteouic )
-
27 Aug 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free